Moreover the EBV-specific humoral and cellular immunity seems dysregulated in MS patients: there is an increase in anti-EBV antibodies titer years before MS onset [8], a decreased CD8+ EBV response [9] and the presence of polyfunctional myelin/EBV cross-reactive CD4+ T cells in MS patients [10]. The gene discussed is CD8A; the disease is myeloid sarcoma.